Compare RWT & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RWT | PHVS |
|---|---|---|
| Founded | 1994 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 715.8M | 1.7B |
| IPO Year | 1995 | 2021 |
| Metric | RWT | PHVS |
|---|---|---|
| Price | $5.53 | $24.14 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 9 |
| Target Price | $7.00 | ★ $39.44 |
| AVG Volume (30 Days) | ★ 1.7M | 287.2K |
| Earning Date | 02-12-2026 | 11-12-2025 |
| Dividend Yield | ★ 12.88% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $120,897,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $46.22 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.68 | $11.51 |
| 52 Week High | $6.73 | $29.80 |
| Indicator | RWT | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 48.58 | 44.99 |
| Support Level | $5.49 | $23.62 |
| Resistance Level | $5.69 | $28.43 |
| Average True Range (ATR) | 0.13 | 1.49 |
| MACD | -0.02 | -0.13 |
| Stochastic Oscillator | 25.71 | 10.81 |
Redwood Trust Inc is a real estate investment trust focused on different areas of housing credit. The company operates in three segments: Sequoia Mortgage Banking includes mortgage loan conduit that acquires residential consumer loans from third-party originators for sale to whole loan buyers and securitization; CoreVest Mortgage Banking segment includes consists of a platform that originates residential investor loans for securitization, sale, or transfer into Redwood Investments portfolio; and Redwood Investments segment consists of organic investments sourced through mortgage banking operations, including securities retained from Sequoia and CoreVest securitization activities. It derives maximum revenue from Redwood Investments segment.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.